What is DeepScribe?
DeepScribe operates at the intersection of healthcare innovation and machine learning, providing a dual-purpose platform that integrates seamlessly into clinical workflows. The company offers a robust Telemedicine Platform that facilitates remote patient access while simultaneously automating the documentation process. By reducing the administrative burden on healthcare providers, DeepScribe enables clinicians to focus on patient outcomes rather than manual data entry, positioning itself as a critical infrastructure player in the modern digital health ecosystem.
How much funding has DeepScribe raised?
DeepScribe has raised a total of $35.2M across 2 funding rounds:
Angel/Seed
$5.2M
Unspecified
$30M
Angel/Seed (2021): $5.2M with participation from Foothill Ventures, Supernode Ventures, 1984 Ventures, Industry Ventures, Skydeck, Stage 2 Capital, Wavemaker Three-Sixty Health, Plug and Play Tech Center, and Sequoia Scout Fund
Unspecified (2022): $30M led by Bee Partners, 1984 Ventures, Stage 2 Capital, and Index Ventures
Key Investors in DeepScribe
Index Ventures
A prominent venture firm that partners with entrepreneurs from seed to IPO, known for backing transformative companies that challenge the status quo.
Stage 2 Capital
A venture capital fund comprised of go-to-market experts that provides operational expertise and data-driven frameworks to help B2B software companies scale revenue.
Bee Partners
A pre-seed venture capital fund focused on human-machine interaction and machine learning, supporting expert founders in building the next generation of technological advancements.
What's next for DeepScribe?
With the recent infusion of capital, DeepScribe is poised to scale its enterprise-level operations and expand its market footprint. The strategic focus will likely center on enhancing the accuracy of its AI-driven transcription models and deepening integration capabilities with existing Electronic Health Record (EHR) systems. As the demand for remote healthcare solutions continues to rise, the company is expected to leverage its backing to solidify its position as a leader in automated clinical intelligence, potentially exploring new therapeutic areas and international market expansion to sustain its growth trajectory.
See full DeepScribe company page
